[1] MAO L, ZHENG Q T, LV Y. Progress on the study of solid drug polymorphism. Nat Prod Res Dev(天然产物研究与开发), 2005, 17(3): 371-375.
[2] LV Y, DU G H. Crystalline drug(晶型药物).Beijing: People′s Medical Publishing House Co., LTD, 2009: 6-7.
[3] ZHENG L L. Effect of drug polycrystalline on drug quality. China Pharm(中国药师), 2008,(3): 347-349.
[4] YANG S Y, ZHOU J, ZHANG L, et al. Present situation and progress of the research for polymorphic chemical drugs in China. Her Med (医药导报), 2019, 38(2): 177-182.
[5] MACHER A, CROKER D M, SEATON C C, et al. Solution-mediated polymorphic transformation: form Ⅱ to form Ⅲ piracetam in organic solvents . Cryst Growth Des, 2014, 14(8): 3967-3974.
[6] LU M, GONG Y, DU W, et al. The effect of solvent on crystal transformation process of prasugrelhydrogen sulfate and its mechanism. Chin J New Drugs(中国新药杂志), 2021, 30(17): 1616-1620.
[7] CHEN J. Research progress of drug polymorphic transformation factors. Tianjin Pharm (天津药学), 2018, 30(6): 44-48.
[8] AN J H, CHOI G J, KIM W S. Polymorphic and kinetic investigation of adefovirdipivoxil during phase transformation. Int J Pharm, 2012, 422(1-2): 185-193.
[9] PAISANA M C, WAHL M A, PINTO J F. Role of moisture on the physical stability of polymorphic olanzapine. Int J Pharm, 2016, 509(1-2): 135-148.
[10] XIN C F, JING W L, YU L, et al. Optimization of crystallization conditions of lactitol. Food Res Dev(食品研究与开发), 2016, 37(3): 129-131.
[11] LU H B, GENG L, WANG P, et al. Effects of cooling rates and stirring speeds on the crystalline form of febuxostat. Acta Acad Med Xuzhou(徐州医科大学学报),2015,(12):855-857.
[12] BRITTAIN H G. Effects of mechanical processing on phase composition. J Pharm Sci, 2002, 91(7): 1573-1580.
[13] WILLART J F, DESCAMPS M. Solid state amorphization of pharmaceuticals. Mol Pharmacol, 2008, 5(6): 905-920.
[14] ZHANG P, YANG C H, LIU J H, et al. Advances in the studies on the drug polymorphs. Strait Pharm J(海峡药学), 2013, 25(12): 5-8.
[15] LIN S Y, HSU C H, KE W T. Solid-state transformation of different gabapentin polymorphs upon milling and co-milling. Int J Pharm, 2010, 396(1-2): 83-90.
[16] CHEN J X. Study on telmisartan polycrystalline and its crystallization and properties . Zhengzhou:Henan University of Technology, 2015.
[17] SOMANI R H, HSIAO B S, NOGALES A, et al. Structure development during shear flow-induced crystallization of i-PP: in-situ small-angle X-ray scattering study. Macromolecules, 2000, 33(25): 9385-9394.
[18] SYPEK K, BURNS I S, FLORENCE A J, et al. In situ monitoring of stirring effects on polymorphic transformations during cooling crystallization of carbamazepine. Cryst Growth Des, 2012, 12(10): 4821-4828.
[19] GAO J, TENG Z J, SHU J H, et al. Drug polymorphic transformation during manufacturing process of solid dosage forms. Chin J New Drugs (中国新药杂志), 2018, 27(9): 1000-1005.
[20] MARIA V R, JUAN Z D, PILAR J. Effect of pressure on the polymorphic forms of famotidine. Thermochim Acta, 2002, 394(1): 19-24.
[21] MAZEL V, DELPLACE C, BUSIGNIS V, et al. Polymorphic transformation of anhydrous caffeine under compression and grinding: a re-evaluation. Drug Dev Ind Pharm, 2011, 37(7): 832-840.
[22] JAMES J D Y, PUPA G, NICO S, et al. Crystallization by particle attachment in synthetic, biogenic, and geologic environments. Science, 2015, 349(6247): aaa6760. Doi: 10.1126/science.aaa6760.
[23] WATANABE M, MIZOGUCHI M, AOKI H,et al. Saturated fatty acids andfatty acid esters promote the polymorphic transition of clarithromycinmetastable form I crystal.Int J Pharm, 2016, 512(1): 108-117.
[24] TAKAKO I, FUMITOSHI H, DAISUKE I, et al. Crystallization and polymorphic transitions of chlorpropamide in aqueous 2-hydroxybutyl-β-cyclodextrin solution. Eur J Pharm Sci, 2009, 39(4): 248-255.
[25] TAMURA R, MIZUTA M, YABUNAKA S, et al. Induction and inhibition of preferential enrichment by controlling the mode of the polymorphic transition with seed crystals. Chemistry, 2006, 12(13): 3515-3527.
[26] WANG Z. Controllable preparations of polymorphic form of tolfenamic acid and the formation of salt between piperazine and tolfenamic acid. Jinan:Shandong University, 2020.
[27] INSORN P, KITIYANAN B. Selective hydrogenation of concentrated vinylacetylene mixed C4 by modified Pd catalysts: effect of Cu. Catalysts, 2016, 6(12): 199-210.
[28] YOUSEF M, VANGALA V. Pharmaceutical co-crystals: molecules, crystals, formulations, medicines. Cryst Growth Des, 2019, 19(12): 7420-7438.
[29] SCHULTHEISS N, NEWMAN A. Pharmaceutical cocrystals and their physicochemical properties. Cryst Growth Des, 2009, 9(6): 2950-2967.
[30] SAMIE A, DESIRAJU G, BANNIK M. Salts and cocrystals of antidiabetic drugs, gliclazide, tolbutamide and glipizide: solubility enhancements through drug-coformer interactions. Cryst Growth Des, 2017, 17(5): 2406-2417.
[31] MORADIVA H, ISLAM M, WOOLLAM G, et al. Continuous cocrystallization for dissolution rate optimization of a poorly water-soluble drug. Cryst Growth Des, 2014, 14(1): 189-198.
[32] MASUDA T, YOSHIHAHSI Y, YONEMOCHI E, et al. Cocrystallization and amorphization induced by drug-excipient interaction improves the physical properties of acyclovir. Int J Pharm, 2012, 422(1): 160-169.
[33] JIANG Y H. Use cocrystal technology to improve the physical properties and stability of hydroxytyrosol.Beijing:University of Chinese Academy of Sciences, 2021.
[34] NEWMAN A. Specialized solid form screening techniques. Org Proc Res Dev, 2013, 17(3): 457-471.
[35] SRIRAMBHATLA V K, GUO R, PRICE S L, et al.Isomorphous template in-ducedcrystallisation: A robust method for the targeted crystallisation of computationally predicted metastable polymorphs. Chem Comm, 2016, 52(46): 7384-7386.
[36] CHADWICK K, CHEN J, MYERSON A S, et al. Toward the rational designof crystalline surfaces for heteroepitaxy: Role of molecular function-ality. Cryst Growth Des, 2012, 12(3): 1159-1166.
[37] PEDRO M V, ERIC M P, MINSOUNG R, et al. Microfluidic platform for combinatorial synthesis and optimization of targeted nanoparticles for cancer therapy. ACS Nano, 2013, 7(12): 10671-10680.
[38] DUNCANSON W J, LIN T, ABATE A R, et al. Microfluidic synthesis of advanced microparticles for encapsulation and controlled release. Lab Chip, 2012, 12(12): 2135-2145.
[39] JEBRAIL M J, BARTSCH M S, PATEL K D. Digital microfluidics: A versatile tool for applications in chemistry, biology and medicine. Lab Chip, 2012, 12(14): 2452-2463.
[40] LIU D, ZHANG H, FONTANA F, et al. Microfluidic-assisted fabrication of carriers for controlled drug delivery. Lab Chip, 2017, 17(11): 1856-1883.
[41] CATHERINE T L, ANDREAS J, LAURIE E L, et al. Controlled self-assembly of monodisperse niosomes by microfluidic hydrodynamic focusing. Langmuir Acs J Surf Coll, 2010, 26(11): 8559-8566.
[42] HOOD R R, VREELAND W N, DEVOE D L. Microfluidic remote loading for rapid single-step liposomal drug preparation. Lab Chip, 2011, 14(17): 3359-3367.
[43] BHAMIDI V, LEE S H, HE G, et al. Antisolvent crystallization and polymorph screening of glycine in microfluidic channels using hydrodynamic focusing. Cryst Growth Des, 2015, 15(7): 3299-3306.
[44] LU J, LITSTER J D, NAGY Z K. Nucleation studies of active pharmaceutical ingredients in an air-segmented microfluidic drop-based crystallizer. Cryst Growth Des,2015, 15(80): 3645-3651.
[45] GOYAL S, ECONOMOU A, PAPADOUPOLOS T, et al. Solvent compatible microfluidic platforms for pharmaceutical solid form screening. RSC Adv, 2016,6(16): 13286-13296.
[46] GOYAL S, THORSON M R, ZHANG G G Z, et al. Microfluidic approach to cocrystal screening ofpharmaceutical parent compounds. Cryst Growth Des, 2012, 12(12): 6023-6034.
[47] SHI H, XIAO Y, FERGUSON S, et al. Progress of crystallization in microfluidic devices. Lab Chip, 2017, 17(13): 2167-2185.
[48] CHEN K, GOH L, HE G, et al. Identification of nucleation rates in droplet-basedmicrofluidic systems. Chem Eng Sci, 2012, 77: 235-241.
[49] OUYANG J B, CHEN J, YING X, et al. Research progress on polymorph control of small molecule drugs. Mod Chem Ind(现代化工), 2021, 41(1): 62-66,71.
[50] THORSON M R, GOYAL S, GONG Y, et al. Microfluidic approach to polymorph screening through antisolvent crystallization. Cryst Eng Comm, 2012, 14: 2404-2412.
[51] VENKATESWARLU B, LEE SH, HE G, et al. Antisolvent Crystallization and Polymorph Screening of Glycine in Microfluidic Channels Using Hydrodynamic Focusing. Cryst Growth Des, 2015, 15(7): 3299-3306.
[52] SIMONE E, MCVEIGH J, REIS NM, et al. A high-throughput multi-microfluidic crystal generator(MMicroCryGen)platform for facile screening of polymorphism and crystal morphology for pharmaceutical compounds. Lab Chip, 2018, 18(15): 2235-2245.
[53] WIJETHUNGA T K, BAFTIZADEH F, STOJAKOVIC J, et al. Experimental and mechanistic study of the heterogeneous nucleation and epitaxy of acetaminophenwith biocompatible crystalline substrates. Cryst Growth Des, 2017, 17(7): 3783-3795.
[54] HENG T, YANG D, WANG R, et al. Progress in Research on Artificial Intelligence Applied to Polymorphism and Cocrystal Prediction. ACS Omega, 2021, 6(24): 15543-15550.
[55] JOHNSTON A, JOHNSTON B F, KENNEDY A R, et al.Targeted crystallisation of novel carbamazepine solvates based on aretrospective random forest classification. Cryst Eng Comm, 2008, 10(1): 23-25.
[56] XIN D, GONNELLA N C, HE X, et al. Solvate prediction for pharmaceutical organic molecules with machine learning. Cryst Growth Des, 2019, 19: 1903-1911.
[57] CLYDESDALE G, DOCHERTY R, ROBERTS K J. HABIT-a program for predicting the morphology of molecular crystals.Comp Phys Comm, 1991, 64(2):311-328.
[58] HOLLEMAN E T, DUGUID E, KEEFE L J, et al. Polo: an open-source graphical user interface for crystallization screening. J Appl Crystallogr, 2021, 54(2): 673-679.
[59] WANG Y Y, YANG Y J, LIU M M, et al. Phenomenon and progress on the study of solid drug polymorphism. Shandong Chem Ind(山东化工), 2021, 50(3): 79-80.
[60] ZHANG W J, LI D H, LV C Y, et al. Application progress of drug crystal forms in drug research. J Pharm Res, 2021, 40(4): 266-271.
[61] DU C, LIU XN, TANG Y, et al. Comparative study of thermal stability and crystal form of bendamustine hydrochloride. J Yichun Univ(宜春学院学报), 2021, 43(6): 38-42.
[62] ROSA P, CHIARA S, GUIDO E, et al. The effect of diethylene glycol monoethyl ether on skin penetration ability of diclofenac acid nanosuspensions. Coll Surf B Biointerfaces, 2018, 162: 8-15.
[63] LIANG Y, XING C, ZHOU Q M, et al. Preparation of three crystals of mifepristone and its pharmacokinetics in rats. Chin New Drugs J(中国新药杂志), 2020, 29(19): 2251-2259.